WILMINGTON, Mass. & MARCO ISLAND, Fla. -- (BUSINESS WIRE) -- Kapa Biosystems, Inc., a leading supplier of reagents for the life science market, today announced the launch of products that improve performance and workflows for genomic research. The new suite of products enables researchers to apply the latest next-generation sequencing (NGS) technologies more effectively to millions of low quality and challenging samples, such as formalin-fixed paraffin-embedded (FFPE) tissue common in cancer profiling. Kapa Biosystems and its customers will present data supporting the new products during the 2014 Advances in Genome Biology and Technology (AGBT) Meeting in Marco Island, Fla. on February 12-15.
“We remain focused on delivering innovative products that help unlock the genetic code and provide insights into the transcriptome as we drive towards a more holistic, systems biology understanding of genetics,” said Brian Komorous, Director of Marketing at Kapa Biosystems. “With these new products, we are building on the success of our DNA sequencing solutions and expanding into RNA sequencing markets, with the goal of improving performance and sequencing quality.”
Multiple Products to Accelerate DNA & RNA Research
Kapa Biosystems offers a portfolio of high-performance reagents for use in PCR, qPCR, NGS, and molecular diagnostics applications. The reagents contain novel enzymes that confer significant performance advantages when compared to traditional wild-type enzymes. Many of the products are optimized for high-throughput workflows, and include pre-validated scripts using the leading liquid handling automation platforms.
The latest NGS products offer significant workflow and performance advantages over competitive offerings.
Later this year, Kapa Biosystems will continue to add to its RNA product portfolio with additional pre-validated solutions using leading liquid handling platforms for NGS applications.
Continued Commercial Growth and Expansion
Last month, Kapa Biosystems announced several high-profile additions to its management team, along with the relocation of its corporate and international headquarters to larger facilities in Wilmington, Mass. and Cape Town, South Africa respectively. Combined, these new locations offer more than 25,000 square feet, which more than doubles the company’s previous facility investment. These new hires and larger facilities enable the company to scale enzyme production, quality control and manufacturing capacity across its four business franchises, increase headcount and expand R&D initiatives to better serve its growing number of customers around the world.
About Kapa Biosystems
Kapa Biosystems is a life science reagents supplier that employs proprietary, directed evolution technologies to optimize enzymes for PCR, real-time PCR, next generation sequencing and molecular diagnostic applications. Kapa Biosystems offers a portfolio of best-in-class products containing novel enzymes that confer significant performance advantages when compared to traditional wild-type enzymes. The company is based in Wilmington, Massachusetts with a research, development and manufacturing facility in Cape Town, South Africa. For more information, please visit www.kapabiosystems.com
KAPA is a trademark of Kapa Biosystems. All other brands may be trademarks of their respective holders.
Kapa Biosystems’ products are for Research Use Only; not for use in diagnostic procedures.